Search Results
Your search for ,ALl matches 18393 pages
Showing 1751 - 1800Venetoclax Plus Hypomethylating Agents: Analyzing Standard-of-Care Outcomes in Older Patients With AML
Standard-of-care treatment comprising venetoclax plus hypomethylating agents was found to be safe and effective in some patients aged 80 years and older with acute myeloid leukemia (AML), according to a recent study published by Madarang et al in Blood Neoplasia. Background Older adult patients...
A Delay in Diagnosis Led to Advanced Prostate Cancer
Cancer is not an unfamiliar disease to me. My mother died of cancer when I was 12. My oldest sister died of breast cancer, an aunt died of cancer (I don’t know which type), and my older brother is a prostate cancer survivor. So, when I was diagnosed with prostate cancer in October 2021, the news...
Pirtobrutinib in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
On December 1, 2023, pirtobrutinib (Jaypirca), a selective, noncovalent Bruton’s tyrosine kinase (BTK) inhibitor that inhibits both wild-type and C481-mutant BTK with equal low nanomolar potency and is designed to address several of the limitations of covalent BTK inhibitors, was granted...
Enfortumab Vedotin-ejfv Plus Pembrolizumab Improves Survival vs Platinum-Based Chemotherapy in Advanced Urothelial Cancer
As reported in The New England Journal of Medicine by Thomas Powles, MD, Barts Cancer Institute Biomedical Research Centre, Queen Mary University of London, and colleagues, the phase III EV-302 trial has shown that the combination of the antibody–drug conjugate enfortumab vedotin-ejfv, which is...
Whole-Pelvic Radiation Therapy for Unfavorable-Risk Prostate Cancer
As reported in the Journal of Clinical Oncology by Sayan et al, analysis of long-term findings from the phase III Dana-Farber Cancer Institute Trial 05-043 showed that whole-pelvic radiation therapy (WPRT) was associated with favorable survival outcomes vs prostate-only radiation therapy (PORT)...
Head and Neck Cancer: Osteoradionecrosis of the Jaw Classification System
In a single-institution study reported in the Journal of Clinical Oncology, Watson et al identified risk factors for osteoradionecrosis of the jaw and developed a classification system for the condition in patients receiving radiation therapy for head and neck cancer. Study Details The study...
Impact of Age on Outcomes in Endometrial Cancer
In an analysis of data from the PORTEC-1, -2, and -3 trials reported in The Lancet Oncology, Wakkerman et al found that older age was associated with more aggressive tumor features and poorer outcomes in patients with endometrial cancer. Study Details The analysis included data from 1,801...
New Policy Statement Addresses Social, Economic, and Environmental Factors Influencing Cancer Care, Outcomes
ASCO’s new policy statement highlights the need for formalized efforts to address health-related social needs and outlines ways to address social determinants of health (SDOH) in cancer care. Social determinants are defined as conditions in which people are born, grow, live, work, and age, which...
America’s Cancer Doctors Demand Action From Congress: Address Drug Shortages
Cancer doctors from across the United States are lending their voices to a new advocacy campaign to end drug shortages. Led by the Association for Clinical Oncology (ASCO), nearly 500 oncology professionals have signed an open letter to Congress and the administration highlighting the severe impact ...
KEYNOTE-756 Additional Findings: Pembrolizumab Shown to Be Beneficial Regardless of Age, Menopausal Status
In updated findings from the phase III KEYNOTE-756 trial, the addition of pembrolizumab to chemotherapy in the neoadjuvant setting improved the rates of pathologic complete response for patients with high-risk estrogen receptor–positive, HER2-negative breast cancer, regardless of their age or...
DUO-E Trial: Results Support New Treatment Options in Endometrial Cancer
New research findings have highlighted the importance of personalized treatment approaches with the monoclonal antibody durvalumab based on mismatch repair (MMR) status in newly diagnosed patients with advanced or recurrent endometrial cancer, according to data presented during the Society of...
Bispecific Antibody Plus Chemotherapy Improves Survival in Patients With Gastric or Gastroesophageal Junction Cancer
Treatment with the first-in-class PD-1/CTLA-4 bispecific antibody cadonilimab plus XELOX (capecitabine, oxaliplatin) chemotherapy demonstrated a survival advantage for patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma as first-line treatment, regardless of PD-L1...
ASCO Survey Finds Oncologists’ Well-Being Worsened Over the Past Decade—but Steps Can Be Taken to Mitigate Burnout
A recent survey by ASCO measuring postpandemic burnout among oncologists in the United States shows that professional satisfaction and work-life balance have significantly deteriorated over the past decade, with 59% of respondents reporting one or more symptoms of burnout, compared with 34% in...
Two Studies Support Deintensification of Treatment for HPV-Associated Oropharyngeal Cancer
Two studies presented at the 2024 Multidisciplinary Head and Neck Cancers Symposium added support for the deintensification of radiotherapy in early-stage oropharyngeal squamous cell cancers associated with the human papillomavirus (HPV), a subtype typically more responsive to therapy compared to...
Addition of Durvalumab to Gemcitabine/Cisplatin in Advanced Biliary Tract Cancer: PROs in TOPAZ-1
As reported in The Lancet Oncology by Howard A. Burris III, MD, FACP, FASCO, and colleagues, a patient-reported outcome (PRO) analysis from the phase III TOPAZ-1 trial showed no “detrimental effect” with the addition of durvalumab to gemcitabine/cisplatin in patients with advanced biliary tract...
Omission of Axillary Dissection After Nodal Downstaging With Neoadjuvant Chemotherapy in Breast Cancer
In a retrospective cohort study reported in JAMA Oncology, Montagna et al found that patients with breast cancer with nodal downstaging after neoadjuvant chemotherapy had a low rate of axillary recurrence, with no difference observed for staging with targeted axillary dissection vs sentinel lymph...
Local Recurrence of Endometrial Cancer: Radiotherapy With or Without Cisplatin
As reported in the Journal of Clinical Oncology by Ann H. Klopp, MD, PhD, and colleagues, results from an NRG Oncology/GOG trial showed “excellent” progression-free survival outcomes with radiation therapy alone for local recurrences of endometrial cancer, with the addition of cisplatin in...
Historical Community Outreach and Engagement Efforts at NCI-Designated Cancer Centers
Investigators have examined the historical evolution of Community Outreach and Engagement initiatives at the National Cancer Institute (NCI) and NCI-designated cancer centers and provided recommendations to guide future efforts, according to a recent study published by Pohl et al in CA: A Cancer...
Selective Targeting of PARP1 in Early-Phase Study Shows Activity in Breast Cancer
Saruparib, a first-in-class PARP1-selective inhibitor, was reported to have favorable safety and anticancer activity in heavily pretreated patients with breast cancer harboring homologous recombination–repair (HRR) mutations, according to the results of the phase I/II PETRA study presented at the...
Newly Identified Biomarkers May Improve Diagnosis and Treatment of RCC Subtypes
Researchers have identified novel biomarkers in renal cell carcinoma subtypes, according to a new study published by Li et al in Cell Reports Medicine. The findings may help identify therapeutic targets in non–clear cell renal cell carcinomas. Background Renal cell carcinoma is a diverse cancer...
Hemihepatectomy: Outcomes With Laparoscopic vs Open Surgery
In a phase III study (ORANGE II PLUS) reported in the Journal of Clinical Oncology, Fichtinger et al found that among patients with indications for hemihepatectomy suitable for both laparoscopic and open approaches, of whom the majority had cancer, the laparoscopic approach was associated with a...
Dato-DXd in Advanced or Metastatic HR-Positive/HER2-Negative or Triple-Negative Breast Cancer
In the phase I TROPION-PanTumor01 trial reported in the Journal of Clinical Oncology, Aditya Bardia, MD, PhD, and colleagues found that the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) was active in patients with locally advanced or metastatic hormone receptor...
United Kingdom’s First Cardio-Oncology Service: 10-Year Experience
In a research letter published by Andres et al in JACC: CardioOncology, staff from Royal Brompton Hospital, Guy’s and St. Thomas’ NHS Foundation Trust in London described their experience over 10 years in the UK’s first cardio-oncology service. Study Details The study involved data from the initial ...
Breast-Conserving Therapy in BRCA-Mutation Carriers: Study Looks at Long-Term Outcomes
Recent research has provided valuable insights into the long-term outcomes of patients with pathogenic BRCA1 and BRCA2 mutations who undergo breast-conserving therapy, according to a study presented at the 2024 Society of Surgical Oncology (SSO) Annual Meeting.1 The observational study found that...
Relapsed or Refractory CD7-Positive Leukemia or Lymphoma: CAR T-Cell Therapy Plus HSCT Without GVHD Prophylaxis
In a Chinese study reported in The New England Journal of Medicine, Hu et al found that sequential CD7 chimeric antigen receptor (CAR) T-cell therapy and allogeneic hematopoietic stem cell transplantation (HSCT) without graft-vs-host disease (GVHD) prophylaxis was effective in patients with...
Mortality Trends Among Asian American, Native Hawaiian, and Other Pacific Islander Patients With Preventable Cancers
The American Cancer Society (ACS) has detailed disparities in the mortality rates for preventable cancer types among Asian American, Native Hawaiian, and other Pacific Islander patients in a new Cancer Facts & Figures report published by Wagle et al. Background In this report, the Asian...
Pediatric AML: Comparison of Induction Regimens
In the phase III AML2012 trial, which had early termination of enrollment and results of which were reported in the Journal of Clinical Oncology, Tierens et al found that mitoxantrone-based induction resulted in better outcomes vs liposomal daunorubicin–based induction in pediatric patients with...
Breast Implant–Related Cancers: Should Our Patients Be Concerned?
The U.S. Food and Drug Administration (FDA) issued a safety communication,1 which was updated2 on March 22, 2023, informing the public that there have been reports of squamous cell carcinomas (SCC) and various lymphomas of the breast in the capsule or scar of breast implants. These lymphomas are ...
USPSTF Issues Final Recommendation Statement on Screening for Breast Cancer
Today, the U.S. Preventive Services Task Force (USPSTF) published a final recommendation statement on screening for breast cancer. The USPSTF now recommends that all women get screened for breast cancer every other year starting at age 40 and continuing through age 74 (B grade recommendation). More ...
Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk ALL
In an analysis from the Children’s Oncology Group phase III AALL1131 study reported in the Journal of Clinical Oncology, Alexander et al found that exposure to propofol was associated with an increased risk of impairment in reaction time/processing speed at 1 year after treatment in children with...
Combination of Preketone Supplements and Immunotherapy May Be Effective in Patients With Prostate Cancer
The addition of a component of the ketogenic diet—a preketone dietary supplement—to immunotherapy showed efficacy in potentially treating prostate cancer in a laboratory setting, according to a recent study published by Murphy et al in Cancer Research. Background Although immune checkpoint blockade ...
Trends in Hematopoietic Cell Transplantation Survival Rates Across Racial and Ethnic Groups
The rate of survival following autologous and allogeneic hematopoietic cell transplantation may have increased among all racial and ethnic groups, but disparities may still exist among some patient groups, according to a recent study published by Khera et al in Blood Advances. Background Autologous ...
MRI-Guided Duration of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
In a Dutch phase II study (TRAIN-3) reported in The Lancet Oncology, Anna van der Voort, MD, and colleagues found that magnetic resonance imaging (MRI) detected complete radiologic response after only three cycles of neoadjuvant chemotherapy in many patients with stage II to III HER2-positive...
Immunotherapy Plus FOLFIRI for Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
In a French noncomparative phase II trial (PRODIGE 59-FFCD 1707-DURIGAST) reported in JAMA Oncology, Tougeron et al found limited activity of FOLFIRI (leucovorin, fluorouracil, and irinotecan) plus durvalumab or durvalumab/tremelimumab in the second-line treatment of advanced...
Barriers to Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
Investigators have uncovered persistent racial and social disparities that may impede access to autologous hematopoietic cell transplantation for some patients with multiple myeloma, according to a recent study published by Esteghamat et al in Clinical Lymphoma, Myeloma & Leukemia. Background...
Combined ICI and VEGF Inhibitor Trials in Cancer: Cardiovascular Eligibility Criteria and Adverse Event Reporting
In a study reported in JACC:CardioOncology, Rankin et al analyzed the degree to which published phase II to IV trials of combination immune checkpoint inhibitor (ICI) and VEGF inhibitor treatment for cancer reported cardiovascular eligibility criteria and adverse events. As stated by the...
Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being
Investigators have uncovered that the emotional and physical health of breast cancer survivors may be influenced by their relationship with their partners, according to a recent study published by Vachon et al in Healthcare. Background The diagnosis and treatment of breast cancer often place...
Pamela Kunz, MD, Named Editor-in-Chief of New JCO Oncology Advances
ASCO recently announced the upcoming launch of JCO Oncology Advances (JCO OA), a new open-access and interdisciplinary journal. Pamela Kunz, MD, will serve as the new Editor-in-Chief of this innovative journal, dedicated to accelerating progress in the global fight against cancer by providing a...
Rapid Guideline Update Supports Capivasertib for Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer now have a new medication option that extends survival, according to an ASCO rapid guideline update.1 The update was designed to orient clinicians to outcomes from the CAPItello-291 trial, which led to the U.S. Food...
Activity Shown for Antibody-Drug Conjugates in Gynecologic Cancers
The recent approval of mirvetuximab soravtansine-gynx is a testament to the emerging benefit of antibody-drug conjugates in recurrent ovarian cancer. Other agents of this class are now eliciting excitement as they demonstrate high response rates in a population with unmet clinical needs, according...
Can HPV Circulating Tumor DNA Guide Adjuvant Treatment of Oropharyngeal Cancer?
Although so-called liquid biopsies are now helping to determine the need for adjuvant therapy for a number of malignancies, oropharyngeal carcinoma is not yet one of them, according to a prospective pilot study from Memorial Sloan Kettering Cancer Center. The investigators evaluated the use of...
Survival Benefit Emerges With Use of Dostarlimab-gxly Plus Chemotherapy in Advanced or Recurrent Endometrial Cancer
The addition of a checkpoint inhibitor to standard chemotherapy as first-line treatment of advanced or recurrent endometrial cancer not only reduced the risk of disease progression but improved overall survival, particularly for the mismatch repair–deficient/microsatellite instability–high...
Adagrasib Plus Cetuximab: Potential Option for KRAS G12C–Mutated Colorectal Cancer
Although KRAS was once considered an untargetable mutation, KRAS inhibitors are now approved for the treatment of KRAS-mutated non–small cell lung cancer (NSCLC) and are emerging as a potential option for the treatment of KRAS G12C–mutated colorectal cancer in combination with other therapies....
Breast Cancer Stalked My Family for Generations and Finally Came for Me
My maternal grandmother, mother, and two of my mother’s sisters were all diagnosed with breast cancer when they were relatively young, so I figured one day, the disease would come for me. Breast cancer is the most common cancer diagnosed among Alaska Native women,1 and at a very early age, my...
AI Model May Help Predict Treatment Responses, Select Most Effective Cancer Therapies in Patients With Cancer
Researchers have developed a novel artificial intelligence (AI) model that may accurately predict whether patients with cancer will respond to certain therapies, according to a recent study published by Sinha et al in Nature Cancer. The findings indicated that single-cell RNA sequencing data may be ...
Imaging Drug to Assist in Detection of Cancerous Tissue Following Lumpectomy Approved
Recently, the U.S. Food and Drug Administration (FDA) approved pegulicianine (Lumisight) for adult patients with breast cancer to assist in the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy. Pegulicianine is a...
Induction and Concurrent Vismodegib With Radiation Therapy for Locally Advanced Unresectable Basal Cell Carcinoma
In a phase II study reported in the Journal of Clinical Oncology, Barker et al found that induction treatment with vismodegib followed by concurrent treatment with vismodegib and curative-intent radiation therapy showed efficacy in patients with locally advanced unresectable basal cell carcinoma. ...
Cabozantinib in Metastatic Pheochromocytomas or Paragangliomas
In the single-center phase II Natalie trial reported in The Lancet Oncology, Jimenez et al found that cabozantinib was active in patients with unresectable and progressive metastatic pheochromocytomas or paragangliomas (MPPGs). As stated by the investigators: “Up to 50% of MPPGs are associated with ...
Propofol-Based Anesthesia May Offer Improved Detection of Serrated Polyps During Colonoscopy
Deeper sedation with the anesthetic drug propofol may improve detection of serrated polyps in patients undergoing colonoscopy to screen for colorectal cancer, according to a recent study published by Quaye et al in Anesthesiology. Background Nearly all colorectal cancers start as polyps....
Observing a Healthy Diet May Reduce Risk of Cardiovascular Disease in Breast Cancer Survivors
Following a healthy diet may reduce the risk of cardiovascular disease in female breast cancer survivors, according to a recent study published by Ergas et al in JNCI Cancer Spectrum. Background Cardiovascular disease is one of the leading causes of non–breast cancer–related mortality among...
